Genflow Biosciences PLC Intellectual property Portfolio addition (5772J)
14 December 2022 - 6:00PM
UK Regulatory
TIDMGENF
RNS Number : 5772J
Genflow Biosciences PLC
14 December 2022
PRESS RELEASE
14 December 2022
Genflow Biosciences Plc
("Genflow" or "the Company")
Intellectual property (IP) Portfolio addition:
Patent submitted for transformational treatment of non-alcoholic
fatty liver disease (NAFLD)
Genflow (LSE: GENF), would like to announce that it has filed a
new patent application with the United States Patent and Trademark
Office ("USPTO") that relates to variants of Sirtuin-6 ("SIRT6"),
and the gene variant's therapeutic uses for the treatment of two
disorders involving the liver: non-alcoholic fatty liver disease
("NAFLD"), and non-alcoholic steatohepatitis ("NASH"), an advanced
form of NAFLD (the "Application").
Genflow holds the exclusive licence for this application through
Genflow Biosciences SRL (the Company's Belgian subsidiary).
NAFLD affects approximately 20% of the general population,
meaning this is a significant area for Genflow to be present in the
research space with the potential to change the lives of many
disorder sufferers . The number of people with NASH, I expected to
rise dramatically in future years due to growing obesity rates in
developed nations.
In the past decade, large drugmakers including Allergan, Gilead
and Novartis, have spent billions of dollars acquiring or licensing
medicines designed to treat NASH.
Dr Eric Leire, Founder and CEO of Genflow, said: "I'm proud of
the tremendous progress Genflow has achieved in filing this new
patent, and we look forward to adding to the expanding body of
knowledge about ageing, liver diseases and bolstering our
ever-growing patent portfolio."
IP Portfolio Update: SIRT6 Age-related cases
The international patent application for the use of SIRT6 in the
treatment and prevention of age-related diseases has received its
first positive review from the Patent Cooperation Treaty
Examiner
The PCT Examiner has confirmed the novelty and inventiveness of
Genflow's filing which represents the first significant step on the
path to the patent, [for which Genflow already has an exclusive
license,] being granted.
For further information please contact:
Genflow Biosciences Plc
Dr Eric Leire via Tancredi +44 203 434 2330
Chief Executive
------------------------------
Clear Capital Markets Ltd
------------------------------
Corporate Broker
Jonathan Critchley +44 203 869 6086
Keith Swann +44 203 897 0981
------------------------------
Tancredi Intelligent Communication
Media Relations
------------------------------
Salamander Davoudi +44 7957 549 906
Helen Humphrey +44 7449 226 720
Benedetta Negri da Oleggio +44 7838 029 970
genflowbio@tancredigroup.com
------------------------------
About Genflow
Genflow is a UK-based biotechnology company developing gene
therapies designed to target the ageing process and to reduce and
delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting ageing in humans by using
adeno-associated virus ("AAV") vectors to deliver copies of the
Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into
cells.
Its mission is to increase understanding of the factors that
control and impact lifespan. Genflow researches develop and
commercialise therapeutic solutions to lengthen health span, the
amount of time we live in good health, creating biological
interventions that enable longer and healthier lives. Genflow is
dedicated to the development and commercialisation of novel
therapeutics targeting ageing in dogs and humans. By treating
ageing, Genflow can contribute to a decrease in healthcare costs
and lessen the emotional and societal burden that comes with an
ageing population.
To learn more visit www.genflowbio.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDEADADFSNAFFA
(END) Dow Jones Newswires
December 14, 2022 02:00 ET (07:00 GMT)
Genflow Biosciences (LSE:GENF)
Historical Stock Chart
From Apr 2024 to May 2024
Genflow Biosciences (LSE:GENF)
Historical Stock Chart
From May 2023 to May 2024